It is a heterogeneous disease, and its molecular subtyping is principally based on the expression of the tumor’s estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2). This evidence concerns the gene ERBB2 and neoplasm.